Vidal Health, India’s second-largest TPA service provider, and Serum Institute of India (SII), part of the Cyrus Poonawalla Group, the world’s largest vaccine manufacturer, announced a strategic collaboration to support national efforts in cervical cancer prevention and awareness.
Starting October 1, 2025, Vidal Health’s platform will offer a fully managed, end-to-end, cashless experience for the HPV vaccine. The platform allows users to digitally book doctor appointments at preferred locations, provide consent, and receive certification with zero paperwork. The programme also includes timely dosage reminders, adherence monitoring, and network management to ensure continuity of care.
Vidal Health is a 100 per cent subsidiary of Bajaj Finserv Health, a digital platform that integrates the fragmented healthcare delivery ecosystem and provides services ranging from preventive to prepaid healthcare, including OPD care and telemedicine.
Sanjiv Bajaj, Chairman & Managing Director, Bajaj Finserv, said, “Healthcare in India is experiencing a fundamental shift from reactive, post-illness care to preventive care, driven by awareness and transformative initiatives like Ayushman Bharat. At Bajaj Finserv Health, we are shaping this change by building a digital platform that empowers people to stay healthy, with preventive healthcare at its core. Our collaboration with Serum Institute marks a strong start to our vaccination programme. By equipping individuals and corporates with digital convenience to manage health proactively, we not only help them cut long-term healthcare costs but also contribute to the nation’s sustained well-being.”
Adar Poonawalla, Chief Executive Officer, Serum Institute of India, said, “The HPV vaccine is an important step in preventing cervical cancer, but wider access and awareness are key to its impact. Our collaboration with Vidal Health helps bridge that gap by using technology to deliver the vaccine more efficiently and at scale. This initiative supports our ongoing efforts to make essential vaccines more accessible and improve public health outcomes.”
Neetha Uthaiah, Whole Time Director, Vidal Healthcare Services, said, “The collaboration with Serum Institute is significant in our journey towards making healthcare inclusive and accessible to all. It enables us to deliver transparent and preventive healthcare, in addition to our existing offering of efficient claims processing and a range of wellness programmes. Through this fully managed programme, we aim to reduce hospitalisations and out-of-pocket medical spends, which are high in India, thus optimising the care ecosystem.”
The initiative brings together healthcare providers, vaccine manufacturers, and national digital platforms such as Aarogya Setu to strengthen the healthcare ecosystem. It also expands Vidal Health’s preventive healthcare offering for individuals, including doctor consultations, diagnostic tests, health check-ups, wellness programmes, and health financing options.
The HPV vaccine will be directly available on Vidal Health’s digital platform, ensuring high-quality vaccines with no intermediaries. The platform enables digital registration, cashless payment, and automated tracking of the multi-dose vaccination schedule. Corporate employees can access the vaccine at their workplace or any Vidal Health partner clinic. The programme is designed for transparency, adoption, and affordability across user groups.